GENPREX INC (GNPX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$2.10-1.87%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · GNPX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
GNPX — litigation filed
Dated 2026-11-04
Other Events. On November 4, 2026, Genprex, Inc. (“Genprex” or the “Company”) issued a press release announcing that new research identifying TROP2 expression as a potential predictive biomarker of response to its lead drug candidate, Reqorsa® (quaratusugene ozeplasmid), a gene therapy product, will be presented at the 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place November 18-20, 2026 in Barcelona, Spain. The research collaborators found that low TRO…
Why it matters: Nasdaq gave Genprex more time to meet its $1.00 minimum bid-price rule. Meeting the rule would address the listing risk.
Worry ifGenprex fails to meet Nasdaq’s $1.00 minimum bid-price rule by the deadline set by the Panel.
Less concerning ifGenprex reports that Nasdaq confirmed it met the $1.00 rule by the Panel’s deadline.
Why it matters: Cash from operations reached a $5.14 million outflow in 2026 Q2. A larger outflow could add pressure to fund its work.
Worry ifCash from operations is below -$5.14 million in a reported quarter.
Less concerning ifCash from operations improves to an outflow smaller than -$5.14 million.
Why it matters: REQORSA is Genprex’s lead drug. A clear trial update would show progress on its main goal.
Supportive ifThe Nov. 13 update names a new REQORSA trial milestone, such as patient enrollment or a planned data date.
Worry ifThe update reports no new REQORSA trial milestone, or says a key milestone has been delayed.
Why it matters: The meeting will share work linked to REQORSA’s TUSC2 gene. New data may support or weaken its research case.
Watch forThe GSA talk reports new results that support TUSC2’s role in the studied cell processes.
Also watch forThe GSA talk reports results that do not support that role, or no new results are shared.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$341 on $10,000 · ±3.4% | How much price usually moves either way. |
| Bad day | $1,214 loss on $10,000 · 12.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,859 loss on $10,000 · 98.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The new partner is set to move the diabetes program from research-grade to clinical production. A completed batch would mark progress toward human testing.
Supportive ifGenprex reports that the CDMO has made a clinical-grade batch for the diabetes gene therapy program.
Worry ifGenprex reports that scale-up is delayed, or that no clinical-grade batch has been made.